Peptide Health Lab

Rx hormone track

DHEA

Also known as: Dehydroepiandrosterone, Prasterone

Regulatory status
Rx via compounding
Evidence grade
Human RCT evidence

Last reviewed August 2, 2026 · 11 sources

What DHEA is and how it works

DHEA, or dehydroepiandrosterone, is a steroid hormone made principally by the adrenal cortex, and together with its sulfate ester it is the most abundant circulating steroid in humans.[8] It is not itself a potent androgen. Its significance is as a precursor: peripheral tissues convert it onward into androstenedione, testosterone, and estrogens, so its effects are largely the effects of whatever a given tissue makes out of it. That conversion is measurable. In women with adrenal insufficiency, four months of oral DHEA raised dehydroepiandrosterone, its sulfate, androstenedione, and testosterone from deficient into the normal range;[1] in healthy older adults, the same dose produced a small increase in testosterone and estradiol, most visible in women.[2]

Circulating DHEA sulfate falls markedly with age, and that observation is the entire foundation of the anti-aging hypothesis attached to this compound: if the decline causes age-related deterioration, restoring the concentration should reverse some of it. Reviews describe how extrapolation from animal data, including associations between low levels and reduced lifespan, turned DHEA into a marketed "superhormone" long before human trials could speak to the question.[8]

The distinction that organizes everything below is between two very different clinical situations. In adrenal insufficiency, DHEA production is pathologically lost and giving it back is replacement. In an otherwise healthy older adult, the decline is a physiological feature of aging, and giving DHEA is supplementation against a hypothesis. Randomized trials have tested both, and they did not reach the same conclusion.[4]

What the research actually shows

In adrenal insufficiency, the evidence is positive and specific. A randomized, double-blind crossover trial in 24 women alternated four months of oral DHEA with four months of placebo. The treatment restored deficient androgens to normal and significantly improved overall well-being along with scores for depression and anxiety. That is a real effect on validated instruments in a population with a real deficiency.[1] A later review summarizes convergent findings across this literature: restored hormone concentrations, improved well-being and sexual satisfaction, better insulin sensitivity, and prevention of bone mineral density loss.[8]

In healthy older adults, the same intervention mostly did nothing. The DHEAge study randomized 280 healthy men and women aged 60 to 79 to a year of DHEA or placebo. It found no harmful accumulation of the hormone or its active metabolites, re-established youthful DHEA sulfate concentrations, and reported a narrow set of positive findings concentrated in women over 70: improved bone turnover, increased libido measures, and changes in skin hydration, thickness, sebum production, and pigmentation.[2] The muscle analysis from the same trial measured handgrip strength, isometric and isokinetic knee strength, and thigh cross-sectional area, and found no benefit despite fully restored serum concentrations.[5] A separate four-month crossover trial in 22 healthy men aged 50 to 69 found no effect on sexuality, lipids, bone markers, body composition, or exercise capacity.[4] The largest and longest of these was a two-year randomized trial in 87 elderly men and 57 elderly women. It found no significant effect of DHEA on body composition, peak oxygen consumption, muscle strength, or insulin sensitivity, though femoral neck bone density did increase in treated men.[6]

In menopausal women, a Cochrane review pooled 28 randomized trials covering 1,273 women. It found no evidence of improved quality of life, could not resolve the effect on menopausal symptoms because the constituent trials measured them inconsistently, and identified a small improvement in sexual function alongside a clear increase in androgenic side effects.[9]

Locally applied, DHEA has an approved indication. A phase III randomized, placebo-controlled trial of intravaginal DHEA in 114 postmenopausal women with dyspareunia showed reduced pain severity and improved vaginal pH and cell maturation over 12 weeks.[7] The synthetic equivalent, prasterone, is approved by the FDA for moderate to severe dyspareunia due to menopausal vulvar and vaginal atrophy, and the reviewed pharmacology describes serum hormone concentrations staying within the range seen in untreated postmenopausal women.[11]

Where the evidence is weak

The headline use has been tested and largely failed. Most people encounter DHEA as an anti-aging or vitality supplement. That is precisely the claim with the most negative randomized evidence. Three independent trials restored concentrations to youthful levels without producing the corresponding functional benefit.[4][5][6] Restoring a biomarker is not the same as restoring the function that biomarker was supposed to explain.

Positive findings cluster in subgroups. The bone-turnover, libido, and skin results in the one-year trial were concentrated in women over 70.[2] Subgroup findings from a trial whose overall result was modest generate hypotheses; they do not settle them.

The fertility literature illustrates the pattern exactly. A meta-analysis of DHEA in diminished ovarian reserve found a significant improvement in clinical pregnancy rate across nine studies. When the analysis was restricted to the four randomized trials, the effect vanished. Oocyte yield, cancellation, and miscarriage rates did not differ.[10] When an effect survives only in the non-randomized studies, the most likely explanation is the study design rather than the hormone.

The evidence base is short. One year and two years are the longest well-controlled exposures on record, in trials sized to detect functional change rather than uncommon harm.[2][6] Nothing published describes a decade of use.

And what people actually take is not always what was studied. The trials above used defined preparations under protocol with serum monitoring. The investigators of the largest of them wrote plainly that the availability of DHEA outside the regular pharmaceutical-medical network created a public health problem that only proper long-term trials could address.[2] When commercial DHEA supplement products were assayed in 1998, measured content ranged from none detectable to 150% of the labeled amount, fewer than half of the products sampled met the 90–110% of label expected of a pharmaceutical, and nearly a fifth contained only trace amounts or none at all.[3] That is a single snapshot from a single analysis and nothing has systematically replaced it, which is itself part of the point.

Legal and regulatory status

DHEA occupies an unusual position. In the United States it is sold in oral form as a dietary supplement rather than as an approved drug, and reviews describe it as having been aggressively marketed and sold in large quantities on that basis.[8] The synthetic equivalent, prasterone, is an FDA-approved prescription product for moderate to severe dyspareunia due to menopausal vulvar and vaginal atrophy.[11] It is also prepared through prescription compounding channels as part of hormone-therapy practice. The same molecule therefore carries three different regulatory identities depending on route, formulation, and indication, and evidence generated under one of them does not automatically transfer to another.

The practical consequence is that supplement-channel DHEA is not accompanied by an approved indication, an assigned dose, a required monitoring schedule, or the identity and potency assurances that attach to an approved product. That is not a comment about any particular product; it is what the category means.

Because DHEA converts to testosterone, it is treated as an anabolic agent under the governing anti-doping codes, and its use is a disqualifying issue in tested sport. Anyone competing should confirm the current status against the relevant code for the current season rather than against this page.

Peptide Health Lab does not sell anything, takes no position on how any product reaches anyone, and states the regulatory picture only because it changes what the evidence above can and cannot support.

Questions to bring to a provider

The most useful framing is diagnostic rather than transactional: what, exactly, is the hormone supposed to be fixing, and is there a way to tell whether it did?

  • Is there any reason to suspect adrenal insufficiency, which is the one setting where randomized evidence supports replacement rather than supplementation?[1]
  • Which baseline labs (DHEA sulfate, testosterone, estradiol, a lipid panel) would make it possible to see what the hormone is actually doing, and at what interval would they be repeated?
  • Given that trials restoring youthful concentrations in healthy older adults produced no functional benefit, what specific outcome would justify trying it anyway, and what would count as it not working?[4][5]
  • Does any personal or family history of a hormone-sensitive condition change the discussion, given the demonstrated conversion into androgens and estrogens?[1]
  • If the target symptom is genitourinary rather than systemic, is the locally applied approved product the better-evidenced option?[11]
  • How does this interact with existing hormone therapy, and who is watching the whole endocrine picture rather than one number?
  • If the goal is fertility-related, what does the randomized-only subset of the evidence support?[10]

A clinician who answers "the trials for that use were negative" is reporting the literature accurately.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Replacement in adrenal insufficiency
Human RCT evidence human RCT · review

The strongest positive evidence for this compound, and the setting where it corrects an actual deficiency. In a randomized, double-blind crossover trial in 24 women with adrenal insufficiency, four months of oral DHEA restored low androgen concentrations to the normal range and significantly improved overall well-being and scores for depression and anxiety. A later review summarizes the same picture across studies: restored hormone levels, improved well-being and sexual satisfaction, and preserved bone mineral density.

[1] [8]

Anti-aging supplementation in adults with normal adrenal function
Human RCT evidence human RCT

Tested properly and largely negative. In 22 healthy men aged 50 to 69 with an age-related decline in DHEA sulfate, four months of supplementation restored youthful concentrations but produced no effect on sexuality, lipids, bone markers, body composition, or exercise capacity. A two-year randomized trial in 87 elderly men and 57 elderly women found no significant effect of DHEA on body composition, peak oxygen consumption, muscle strength, or insulin sensitivity.

[4] [6]

Muscle function and strength in older adults
Human RCT evidence human RCT

Not supported. The muscle-function analysis of the DHEAge study measured handgrip strength, isometric and isokinetic knee strength, and thigh cross-sectional area in 280 adults aged 60 to 80 after a year of treatment. Serum concentrations were restored to the young-adult range; the neuromuscular measures were not improved.

[5] [6]

Menopausal symptoms and quality of life
Human RCT evidence review

A Cochrane review of 28 randomized trials in 1,273 peri- and postmenopausal women found no evidence that DHEA improves quality of life, and could not resolve whether it reduces menopausal symptoms because the trials measured them too inconsistently to pool.

[9]

Sexual function in women
Human RCT evidence review · human RCT

A small, genuine signal. The same Cochrane review found DHEA may slightly improve sexual function against placebo, with a standardized mean difference of 0.31. The one-year healthy-aging trial separately reported a significant increase in most libido measures among women over 70. "Slightly" is doing real work in both sentences.

[9] [2]

Bone density and bone turnover
Human RCT evidence human RCT

Narrow and subgroup-dependent. Bone turnover improved selectively in women older than 70 in the one-year trial, assessed by densitometry and markers of osteoclastic activity. In the two-year trial, femoral neck bone mineral density increased in the treated men. Neither result is a fracture outcome.

[2] [6]

Moderate to severe dyspareunia due to vulvovaginal atrophy
Human RCT evidence human RCT · review

The one indication with an approved prescription product behind it, and it is a local rather than systemic use. A phase III randomized, placebo-controlled trial in 114 postmenopausal women found intravaginal DHEA reduced the severity of pain at sexual activity and improved vaginal pH and cell maturation. A subsequent review notes the approved product maintains serum hormone concentrations within the range seen in untreated postmenopausal women.

[7] [11]

Diminished ovarian reserve and IVF outcomes
Human RCT evidence review

A meta-analysis of nine studies, four randomized and five not, found higher clinical pregnancy rates with DHEA pretreatment, odds ratio 1.47. When the analysis was restricted to the randomized trials alone, the effect disappeared (odds ratio 1.08, 95% CI 0.67 to 1.73). Number of oocytes retrieved, cycle cancellation, and miscarriage did not differ. The authors call for larger randomized trials.

[10]

Typical protocol range in the research

  • Randomized double-blind crossover trial in 24 women with adrenal insufficiency, the setting where DHEA replacement corrects a genuine deficiency

    50 mg orally each morning for four months, alternated with four months of placebo and a one-month washout [1]

  • The DHEAge study: 280 healthy men and women aged 60 to 79 in a double-blind, placebo-controlled trial of one year

    50 mg orally daily for 12 months [2] [5]

  • Phase III randomized, double-blind, placebo-controlled trial of intravaginal DHEA (prasterone) in 114 postmenopausal women reporting dyspareunia as their most bothersome symptom

    Intravaginal DHEA at 0.25%, 0.5%, and 1.0% applied locally over a standard 12-week treatment period [7]

The 50 mg figure that dominates discussion of this compound is not a consensus dose. It is the dose the two landmark trials chose, and both the healthy-aging trial and its muscle-function analysis reported that restoring the hormone to youthful concentrations at that dose did not produce the functional benefits the hypothesis predicted. A range that keeps appearing because it was studied is not the same as a range that works.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • Androgenic effects, most commonly acne

    Odds ratio 3.77 (95% CI 1.36 to 10.4) versus placebo across five trials and 376 women in a Cochrane review · This is the most consistently demonstrated adverse effect in the randomized literature, and it is the predictable consequence of giving a precursor that the body converts onward into androgens. The review rated the evidence for it as moderate quality and found no association with other adverse effects in the trials analyzed.

    [9]

  • Conversion into testosterone and estrogens

    Expected pharmacology, demonstrated by serum measurement in multiple randomized trials · In women with adrenal insufficiency, oral DHEA raised dehydroepiandrosterone, its sulfate, androstenedione, and testosterone from low into the normal range. In healthy older adults, a small rise in testosterone and estradiol was observed, particularly in women. This is a hormone, not a vitamin: any personal or family history of a hormone-sensitive condition is a specific reason to raise it with a clinician before considering anything.

    [1] [2]

  • Reductions in total and HDL cholesterol

    Statistically significant in the four-month adrenal insufficiency crossover trial · Alongside the intended hormonal effects, sex hormone–binding globulin, total cholesterol, and HDL cholesterol all decreased significantly. The clinical consequence over years has not been established, which is a reason for a lipid panel to be part of monitoring rather than an afterthought.

    [1]

  • No established long-term safety profile

    Not established beyond the trial durations · The longest well-controlled trials ran one year in 280 healthy older adults and two years in 144 elderly men and women. Neither recorded harmful accumulation of the hormone or its active metabolites at the doses studied, and neither was designed or powered to detect uncommon or long-latency harms. Absence of a signal over one to two years is not a safety demonstration for indefinite use.

    [2] [6]

  • Unregulated exposure through the supplement channel

    Measured once, in a 1998 quality-control analysis of commercial DHEA supplement products: assayed content ranged from none detectable to 150% of the labeled amount, fewer than half of the products sampled fell within the 90–110% of label expected of a pharmaceutical, and nearly a fifth contained only trace amounts or no active ingredient · Most DHEA in the United States is sold as a dietary supplement rather than as an approved drug, and reviews describe it as having been aggressively marketed in large quantities on the strength of extrapolation from animal data. Material distributed that way does not carry the identity, potency, and lot-release assurances that attach to an approved product, and the analysis above is what that difference looked like when someone actually measured it. The consequence for reading the trials on this page is specific rather than general: those trials used defined preparations under protocol with serum monitoring, so a milligram figure taken from a trial and a milligram figure printed on a supplement label are not interchangeable quantities.

    [3] [8] [2]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
DHEA is not supplied as a lyophilized powder. It is dispensed as a finished oral capsule or tablet, and in its approved prescription form as an intravaginal insert. Each is kept according to the storage statement on the container it arrives in, typically controlled room temperature away from heat, light, and moisture.
Reconstitution
Not applicable. DHEA is supplied in finished dosage forms that are used as dispensed: oral capsules and tablets, and an intravaginal insert. There is no lyophilized powder, no diluent, and nothing to mix.
Handling notes
Storage is the least interesting risk here. Because most DHEA in the United States moves as a dietary supplement rather than as an approved drug, the meaningful variable is not how a container is kept but what standard stands behind its contents. The investigators of the largest placebo-controlled aging trial wrote that the availability of DHEA outside the regular pharmaceutical-medical network created a public health problem that only long-term clinical trials could resolve. That was a comment about the product category, not about shelf life.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Goal pages that include DHEA

Each one starts from the goal rather than the molecule, and grades what the evidence supports for that goal specifically.

  • Anti-Aging

    A research reference for the compounds mapped to longevity and healthy aging. It sets out what the randomized human trials of oral NAD+ precursors and DHEA actually measured, why the injected forms have no outcomes evidence at all, and where the rest is mice and cell culture.

  • Sexual health

    A research reference for the compounds mapped to sexual desire and sexual function, one of them FDA-approved with a labeled contraindication, one carrying the largest randomized literature in this library, and one whose approved use is local rather than systemic.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

11 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder